NCT06773481View on ClinicalTrials.gov

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IV
Interventions
BIOLOGICAL

BC008-1A

Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.

BIOLOGICAL

BC008-1A

Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

INDUSTRY